| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Cereblon
CRBN (cereblon), an E3 ubiquitin ligase. |
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[2].
As a cereblon-binding ligand, Lenalidomide-4-OH binds to CRBN and promotes the recruitment of the E3 ubiquitin ligase complex, facilitating the ubiquitination and degradation of target proteins when incorporated into a PROTAC. |
| ln Vivo |
No specific in vivo activity has been reported for this ligand alone; its in vivo effects are observed only after conjugation with a target protein ligand to form a complete PROTAC molecule.
|
| Enzyme Assay |
N/A; as a ligand, its binding affinity to cereblon is typically determined using biophysical methods such as surface plasmon resonance or cellular assays with complete PROTAC constructs.
|
| Cell Assay |
N/A; this compound is not evaluated alone in cell-based assays but is used as a building block to construct cereblon-recruiting PROTAC degraders for cellular studies.
|
| Animal Protocol |
N/A; no animal studies are performed with the ligand alone.
|
| ADME/Pharmacokinetics |
This compound is typically stored as a powder at -20degC. Its solubility is suitable for use as a synthetic intermediate in PROTAC construction. Molecular weight: 260.25.
|
| Toxicity/Toxicokinetics |
This product is intended for laboratory research use only and is not for human therapeutic use. Standard chemical safety precautions should be observed during handling.
|
| References | |
| Additional Infomation |
Lenalidomide-4-OH is a derivative of the immunomodulatory drug lenalidomide, which is clinically approved for multiple myeloma and myelodysplastic syndromes. This derivative serves as a cereblon-binding moiety for PROTAC development.
|
| Molecular Formula |
C13H12N2O4
|
|---|---|
| Molecular Weight |
260.25
|
| Exact Mass |
260.079
|
| CAS # |
1061604-41-8
|
| PubChem CID |
25015582
|
| Appearance |
White to light brown solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
602.9±55.0 °C at 760 mmHg
|
| Flash Point |
318.4±31.5 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.660
|
| LogP |
-0.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
436
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2C=CC=C(C=2CN1C1C(NC(CC1)=O)=O)O
|
| InChi Key |
HGPRKOYQOBYISD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H12N2O4/c16-10-3-1-2-7-8(10)6-15(13(7)19)9-4-5-11(17)14-12(9)18/h1-3,9,16H,4-6H2,(H,14,17,18)
|
| Chemical Name |
3-(7-hydroxy-3-oxo-1H-isoindol-2-yl)piperidine-2,6-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (~192.12 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8425 mL | 19.2123 mL | 38.4246 mL | |
| 5 mM | 0.7685 mL | 3.8425 mL | 7.6849 mL | |
| 10 mM | 0.3842 mL | 1.9212 mL | 3.8425 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
